Five Star Alters Strategy, Its Stock Gets Slammed

In early April, Five Star announced a change in its strategy whereby it will transition out of the management of 108 smaller senior living communities (SLCs) with 7,500 living units (with an average of 69.4 units per community), close and reposition 27 skilled nursing facilities (SNFs) with 1,500 units located within its continuum of care retirement communities (CCRCs) and close 37 Ageility inpatient rehabilitation clinics that are located within the exited SLCs. The transition is expected to be completed by the end of 2021.

After the transition, Five Star will be left managing 120 communities with 17,906 units. The remaining communities are larger, with an average of 149.2 units per community. They have an average occupancy rate that is about 300 basis points (bp) higher than the company’s average occupancy on March 31 and about 10 full percentage points (1,000 bp) higher than the occupancy on the exited communities and SKFs. Thus, the strategic shift will allow Five Star to focus on managing larger communities where it believes it has a competitive advantage.

In the short run, however, the transition will reduce the management fee income that Five Star receives from the property owner, Diversified Healthcare Trust (DHC). Five Star will also lose the revenues and operating profit from the 37 Ageility rehabilitation clinics that are slated to close.

Prior to the announced strategic shift, I had expected that Five Star would produce earnings per share of $0.23 per share in 2021 and $0.38 per share share in 2022. Now with the loss of revenues and earnings from the transitioned communities and Ageility clinics, I anticipate that the company will report a loss of $0.18 per share in 2021 with earnings rebounding in 2022 to $0.24 per share.

On the day of the announcement, Five Star’s stock fell 13.7% to $5.49. It eventually found a bottom at $4.66 on April 23 and has since recovered some of the ground that it lost. It closed on Friday (May 21) at $5.99.

With the change in the earnings outlook, I have reduced my price target on Five Star’s stock to $7 from $8 previously. However, since the new lower price target represents a 16.9% return from the current quote, I am maintaining my outperform rating on the stock.

Although the transition will present certain challenges especially with the lingering impact of the pandemic, I believe that this is a good strategic step for Five Star, putting it in a better position to grow both the senior living business and Ageility over time. The company will have greater management capacity to pursue new management contracts presumably of larger communities. It also has the financial strength (with little debt and projected available cash of about $70 million by the end of 2022) to grow the business organically or even pursue acquisitions.

My full update report on Five Star Senior Living is available upon request.

May 22, 2021

Stephen P. Percoco
Lark Research
16 W. Elizabeth Avenue, Suite 4
Linden, New Jersey 07036
(908) 975-0250
admin@larkresearch.com

© 2022 by Stephen P. Percoco, Lark Research.   All rights reserved.

This blog post (as with all posts on this website) represents the opinion of Lark Research based upon its own independent research and supporting information obtained from various sources. Although Lark Research believes these sources to be reliable, it has not independently confirmed their accuracy. Consequently, this blog post may contain errors and omissions. Furthermore, this blog post is a summary of a recent report published on this subject and that report provides a more complete discussion and assessment of the risks and opportunities of any investment securities discussed herein. No representation or warranty is expressed or implied by the publication of this blog post. This blog post is for informational purposes only and shall not be construed as investment advice that meets the specific needs of any investor. Investors should, in consultation with their financial advisers, determine the suitability of the post’s recommendations, if any, to their own specific circumstances. Lark Research is not registered as an investment adviser with the Securities and Exchange Commission, pursuant to exemptions provided in the Investment Company Act of 1940. This blog post remains the property of Lark Research and may not be reproduced, copied or similarly disseminated, in whole or in part, without its prior written consent.

This entry was posted in DHC, FVE, Health Care and tagged , . Bookmark the permalink.